|
Inflammatory Bowel Disease: World Market 2010-2025
|
|||||||||||
| Caracteristicas de este estudio de mercado: |
125 seiten | |||||||||||
| Sobre este articulo de mercado: |
Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous y.....
Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous year. We predict that the overall market for IBD drugs will expand from 2010 onwards. Main commercial drivers will be disease prevalence, improving diagnosis and wider access to treatments. Currently, IBD is under-diagnosed, especially in developing countries. As governments and other healthcare providers address chronic illnesses like IBD, this market will expand in many countries. Inflammatory Bowel Disease: World Market 2010-2025 analyses commercial prospects for drugs used to treat IBD, including R&D pipeline developments. How much impact will monoclonal antibodies have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will the European IBD market share compare with the Asian market share in 2015, 2020 and 2025? Our report covers questions such as these, providing answers to benefit your work. In particular, this report covers market prospects for the following agents: • Aminosalicylates/5-ASA • Corticosteroids • Immunomodulators • Antibiotics • Monoclonal antibodies/biologics. The IBD treatment market is complex. Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our new study reveals. Comprehensive analysis of the global IBD drug market Inflammatory Bowel Disease: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 65 tables and figures included, as well as four original interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Report Highlights Companies Listed Abbott Laboratories Amalyte ARCA AstraZeneca Biogen Idec Cambridge Antibody Technology Celltech Pharmaceuticals Centocor Ortho Biotech ChemoCentryx China Medical Cosmo Pharmaceuticals Crohn's and Colitis Foundation of America Crohn's and Colitis Foundation of Canada Dr. Falk Pharma Elan Corporation Enzo Biochem European Federation of Crohn's and Ulcerative Colitis Associations European Medicines Agency (EMEA) Evonik Industries Ferring Pharmaceuticals Food and Drug Administration (FDA) Giaconda Giuliani GlaxoSmithKline Interneuron Isis Pharmaceuticals Johnson & Johnson King's College, London, UK Kyorin Pharmaceutical Co. Medarex Merck and Co. Miltenyi Biotec Nycomed Otsuka Pharmaceutical Group PDL BioPharma Pfizer Probiotic Therapy Research Centre, Sydney, Australia Procter & Gamble Prometheus Laboratories Protein Design Labs Royalty Pharma Salix Pharmaceuticals sanofi-aventis Schering-Plough Shire Pharmaceuticals Group Takeda Pharmaceutical Company Tillots Pharma UCB University of Auckland, New Zealand [Cerrar las informaciones del articulo de mercado] |
|||||||||||
|
1. Executive Summary 1.1 Inflammatory Bowel Disease Market Review 1.2 Aims, Scope and Format of the Report 1.3 Chapter Outlines 1.4 Research and Analysis Methods 2. What Is Inflammatory Bowel Disease? 2.1 Definition 2.2 Types of IBD 2.3 Signs, Symptoms and Associated Conditions 2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations and Other Events 2.3.2 Pyoderma Gangrenosum 2.3.3 Primary Sclerosing Cholangitis 2.4 Ulcerative Colitis 2.5 Crohn's Disease 2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis 2.7 What Causes Inflammatory Bowel Disease? 2.7.1 Genetic Factors 2.7.2 Environmental Factors 2.8 How Common is Inflammatory Bowel Disease? 2.8.1 Geographical Variation in Rates of IBD 2.9 Socioeconomic Costs of IBD 2.9.1 The Individual Cost of IBD 3. Treating Inflammatory Bowel Disease 3.1 Treatment Goals 3.2 Drug Classes Used in IBD Treatment 3.2.1 Aminosalicylates 3.2.2 Corticosteroids 3.2.3 Immunomodulators 3.2.4 Monoclonal Antibodies 3.3 Surgery 3.3.1 Surgery for Ulcerative Colitis 3.3.2 Surgery for Crohn's Disease 3.4 Alternative Treatments 3.4.1 Faecal Bacteriotherapy and Pre/Probiotics 3.4.2 Helminthic Therapy 3.4.3 Complementary Medicine 3.5 Treatment Protocol 3.5.1 Recent Trial Data 4. The World Inflammatory Bowel Disease Market, 2010-2025 4.1 Non-Biologic Drugs 4.1.1 IBD-Specific Drugs (Intestinal Anti-inflammatories) 4.1.2 Drugs not Specific to IBD (Others) 4.2 Biologic Drugs 4.3 Total Market 4.4 Market Shares by Disease Type 4.5 Market Forecast: Inflammatory Bowel Disease Sales 4.6 Market Forecasts: Sales by Disease Type 4.7 Market Forecasts: Sales by Therapy Type 5. Leading Drugs for Inflammatory Bowel Disease, 2010-2025 5.1 Intestinal Anti-inflammatory Drugs 5.2 Asacol 5.2.1 Asacol: Background 5.2.2 Asacol: Sales Forecast and Analysis 5.3 Pentasa 5.3.1 Pentasa: Background 5.3.2 Pentasa: Sales Forecast and Analysis 5.4 Entocort 5.4.1 Entocort: Background 5.4.2 Entocort: Sales Forecast and Analysis 5.5 Lialda 5.5.1 Lialda: Background 5.5.2 Lialda: Sales Forecast and Analysis 5.6 Salofalk 5.6.1 Salofalk: Background 5.6.2 Salofalk: Sales Forecast and Analysis 5.7 Comparison of Intestinal Anti-inflammatory Sales Forecasts 5.8 Biologics 5.9 Remicade 5.9.1 Remicade: Background 5.9.2 Remicade: Sales Forecast and Analysis 5.10 Humira 5.10.1 Humira: Background 5.10.2 Humira: Sales Forecast and Analysis 5.11 Cimzia 5.11.1 Cimzia: Background 5.11.2 Cimzia: Sales Forecast and Analysis 5.12 Tysabri 5.12.1 Tysabri: Background 5.12.2 Tysabri: Sales Forecast and Analysis 5.13 Comparison of Biologic Sales Forecasts 6. The R&D Pipeline for Inflammatory Bowel Disease 6.1 Monoclonal Antibodies 6.1.1 HuZAF 6.1.2 Stelara 6.1.3 Vedolizumab 6.1.4 Simponi 6.2 Small Molecules 6.2.1 Tetomilast 6.2.2 Firategrast 6.3 Antibiotics 6.3.1 Rifaximin 6.3.2 Myoconda 6.4 Nicotine and Buproprion 6.5 Alicaforsen 6.6 Alequel 6.7 MAP Vaccine 6.8 Autologous Stem Cell Transplantation for Crohn's Disease 6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract 7. Leading Companies in the Inflammatory Bowel Disease Sector 7.1 The Largest Companies by Revenue in the Intestinal Anti-inflammatory Market 7.2 Procter & Gamble 7.3 Shire Pharmaceuticals Group 7.4 Prometheus Laboratories 7.5 Ferring Pharmaceuticals 7.6 Kyorin Pharmaceutical 8. Geographical Breakdown of the World IBD Market, 2010-2025 8.1 Intestinal Anti-inflammatory Market: Seven Major Economies 8.2 Intestinal Anti-inflammatory Market: BRICT Countries 8.3 The Global IBD Market: Sales Forecasts by Geographical Area 8.3.1 North America: Sales Forecast, 2010-2025 8.3.2 Europe: Sales Forecast, 2010-2025 8.3.3 Africa, Asia and Australasia: Sales Forecast, 2010-2025 8.3.4 Latin America: Sales Forecast, 2010-2025 8.4 Comparison of Regional Markets: Sales Forecasts, 2010-2025 9. Inflammatory Bowel Disease Market: Opportunities and Challenges Ahead 9.1 SWOT Analysis of the World IBD Market 9.2 Market Drivers 9.2.1 Increasing Disease Incidence 9.2.2 Better Diagnosis 9.2.3 Nature of the Disease 9.2.4 Delivery Systems 9.2.5 Biologics 9.3 Market Restraints 9.3.1 Lack of Understanding of Disease Aetiology 9.3.2 Compliance 9.3.3 Limits of Biologics 9.3.4 A Cure or Vaccine? 10. Interviews with Experts 10.1 Marco Greco 10.1.1 Public Awareness of IBD 10.1.2 The Differences Between European Countries 10.1.3 Drug Companies' Involvement in Awareness Campaigns 10.1.4 Unmet Medical Needs 10.2 Dr Alan Fraser 10.2.1 Autoimmunity vs. Infection Theories 10.2.2 Monoclonal Antibodies 10.2.3 Genotyping 10.2.4 Remaining Therapeutic Gaps 10.2.5 Future Treatments 10.3 Professor Thomas Borody 10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology 10.3.2 IBD and HIV/AIDS 10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments 10.3.4 Potential Cure? 10.3.5 Remicade and MAP 10.3.6 Genotyping 10.3.7 Crohn's vs. Colitis 10.3.8 Future Therapies 10.3.9 Potential and Future of Myoconda 10.4 Professor John Hermon-Taylor 10.4.1 Significance of MAP in Crohn's 10.4.2 The Rising Incidence of IBD 10.4.3 Defining IBD 10.4.4 Timeframe of MAP Vaccine 10.4.5 Antibiotic Activity of Other Crohn's Treatments 10.4.6 Alternative Treatments 10.4.7 Ethics of Crohn's Drug Development 10.4.8 Impact of a Vaccine on the Market 10.4.9 On Claims that MAP is Not Implicated in CD 11. Conclusions of the Study 11.1 IBD Sales to 2025 – How High Will The Market Reach? 11.2 Non-Biologic Treatments 11.3 Biologic Treatments 11.4 Improvements Needed in IBD Treatment 11.5 Future IBD Treatments: R&D Efforts Promising 11.6 The IBD Sector: Looking to the Future Confidently [Cerrar la tabla de contenidos] |
||||||||||||
|
Table 2.1 World Incidence Rates for IBD, 2010 Table 2.2 Prevalence of IBD in Selected Countries, 2010 Table 2.3 Common Misdiagnoses for IBD Table 3.1 Ancillary Drug Types Used in Inflammatory Bowel Disease, 2010 Table 3.2 Composition of Various 5-ASA Drugs Table 4.1 Inflammatory Bowel Disease Market: World Sales and Market Shares by Drug Class, 2009 Table 4.2 Studies Comparing the Direct Medical Costs of Crohn’s Disease and Ulcerative Colitis Table 4.3 World IBD Market: Sales by Disease Type, 2009 Table 4.4 World IBD Market: Sales Forecast, 2010-2025 Table 4.5 World IBD Market: Sales Forecast by Disease Type, 2010-2025 Table 4.6 World IBD Market: Sales Forecast by Therapy Type, 2010-2025 Table 5.1 Top-Five Intestinal Anti-Inflammatory Drugs: World Sales, 2009 Table 5.2 Asacol: World Sales Forecast, 2010-2025 Table 5.3 Pentasa: World Sales Forecast, 2010-2025 Table 5.4 Entocort: World Sales Forecast, 2010-2025 Table 5.5 Lialda: World Sales Forecast, 2010-2025 Table 5.6 Salofalk: World Sales Forecast, 2010-2025 Table 5.7 World Sales Forecasts for Leading Intestinal Anti-Inflammatories, 2010-2025 Table 5.8 Biologics for IBD: World Sales, 2009 Table 5.9 Remicade: World Sales Forecast, 2010-2025 Table 5.10 Contraindications for TNF-a Blockers Table 5.11 Humira: World Sales Forecast, 2010-2025 Table 5.12 Cimzia: World Sales Forecast, 2010-2025 Table 5.13 Tysabri: World Sales Forecast, 2010-2025 Table 5.14 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025 Table 6.1 Key Pipeline Products for Inflammatory Bowel Disease, 2010 Table 7.1 Intestinal Anti-Inflammatories (IAIs): Largest Companies by Revenue, 2009 Table 7.2 Procter & Gamble: Major IAI Products, 2009 Table 7.3 Shire: Major IAI Products, 2009 Table 7.4 Prometheus: Major IAI Products, 2009 Table 7.5 Prometheus: Diagnostic Tests, 2009 Table 7.6 Ferring: Major IAI Products, 2009 Table 7.7 Kyorin: Major IAI Products, 2009 Table 8.1 IBD Markets of Seven Major Economies: Sales and Market Shares, 2009 Table 8.2 IBD Sales and Market Shares for the Major Emerging Markets (BRICT), 2009 Table 8.3 North America: IBD Sales Forecast, 2010-2025 Table 8.4 Europe: IBD Sales Forecast, 2010-2025 Table 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025 Table 8.6 Latin America: IBD Sales Forecast, 2010-2025 Table 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025 Table 9.1 SWOT Analysis of the Global IBD Market, 2010 Figure 2.1 Prevalence of IBD in Selected Countries, 2010 Figure 3.1 Treatment Protocols for Inflammatory Bowel Disease, 2010 Figure 4.1 World IBD Market: Sales Shares by Drug Class, 2009 Figure 4.2 World IBD Market: Sales Shares by Disease Type, 2009 Figure 4.3 World IBD Market: Sales Forecast, 2010-2025 Figure 4.4 World IBD Market: Sales Forecasts by Disease Type, 2010-2025 Figure 4.5 World IBD Market: Sales Forecasts by Therapy Type, 2010-2025 Figure 5.1 Top-Five Intestinal Anti-Inflammatories: World Market Shares, 2009 Figure 5.2 Asacol: World Sales Forecast, 2010-2025 Figure 5.3 Pentasa: World Sales Forecast, 2010-2025 Figure 5.4 Entocort: World Sales Forecast, 2010-2025 Figure 5.5 Lialda: World Sales Forecast, 2010-2025 Figure 5.6 Salofalk: World Sales Forecast, 2010-2025 Figure 5.7 World Sales Forecasts for Leading Intestinal Anti-inflammatory Drugs, 2010-2025 Figure 5.8 Biologics for IBD: World Sales, 2009 Figure 5.9 Remicade: World Sales Forecast, 2010-2025 Figure 5.10 Humira: World Sales Forecast, 2010-2025 Figure 5.11 Cimzia: World Sales Forecast, 2010-2025 Figure 5.12 Tysabri: World Sales Forecast, 2010-2025 Figure 5.13 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025 Figure 7.1 Intestinal Anti-Inflammatories: Largest Companies by Sales, 2009 Figure 8.1 IBD Markets of Seven Major Economies: Sales, 2009 Figure 8.2 IBD Markets of Major Emerging Markets (BRICT): Sales, 2009 Figure 8.3 North America: IBD Sales Forecast, 2010-2025 Figure 8.4 Europe: IBD Sales Forecast, 2010-2025 Figure 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025 Figure 8.6 Latin America: IBD Sales Forecast, 2010-2025 Figure 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025 [Ocultar lista de tablas / figuras] |
||||||||||||
| Precio ** (Formato del reporte): |
libre de costos de envio **Importante: Todos los precios son netos sin impuestos. Depende del país y de su tipo de empresa para pagar los impuestos. Si usted nos da su dirección de facturación, el monto total correcto será indicado en la siguiente orden de proceso. Para más información de impuestos y precios usted nos encuentra en nuestros FAQs |
|||||||||||
